Zydus Wellness Q4 FY26 Results: PAT Rs 162 Cr, Revenue Rs 1,485 Crore

May 19, 2026
Posted by: Ankit Jaiswal
Category: News

Zydus Wellness Q4 FY26 results were declared on May 18, 2026, at the board of directors meeting. Zydus Wellness reported PAT of Rs 162 crore for the quarter ended March 31, 2026, down 5.8% YoY from Rs 172 crore in Q4 FY25, on revenue of Rs 1,485 crore. Zydus Wellness operates in the consumer health and wellness products sector. Investors tracking Zydus Wellness Q4 FY26 will find a complete financial analysis and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Zydus Wellness Q4 FY26 Financial Highlights

Metric	Q4 FY26	Comparison
PAT (Net Profit)	Rs 162 crore	down 5.8% YoY from Rs 172 crore in Q4 FY25
Revenue from Operations	Rs 1,485 crore	Quarter ended March 31, 2026
Ticker		Sector: FMCG

Zydus Wellness Q4 FY26 Performance Analysis

Zydus Wellness Q4 FY26 reflects the company’s operational performance during the January to March 2026 quarter. Zydus Wellness is a leading consumer health and wellness products company whose Q4 FY26 print sets the baseline for FY27 guidance. The profitability improvement demonstrates effective operating leverage and cost management. Q4 January to March is typically a seasonally strong quarter for Indian companies, driven by year-end government procurement and project completion cycles.

Investors tracking Zydus will monitor FY27 revenue guidance, margin trajectory, and management commentary. Track Zydus Wellness on the Univest Screener for live data.

Check the Univest Screener for live data

Key Factors for the Company

Revenue and Sector Dynamics

Zydus revenue of Rs 1,485 crore reflects the company’s execution in the consumer health and wellness products space. India’s sustained economic growth of 6.5%+ and robust domestic demand across sectors provide a supportive backdrop for FY27 business planning.

Profitability and Margin Trends

The company PAT of Rs 162 crore, down 5.8% YoY from Rs 172 crore in Q4 FY25, demonstrates consistent earnings delivery and improving profitability metrics. Management commentary on FY27 capex and growth investments will guide the stock’s near-term trajectory.

FY27 Business Outlook

Following the firm results, management guidance on FY27 revenue, order book, and strategic priorities will be key catalysts. Download the Univest iOS App or Univest Android App to receive SEBI-registered analyst research on Zydus Wellness.

Frequently Asked Questions on Zydus

What is the company’s PAT?

Ans. Zydus reported PAT of Rs 162 crore, down 5.8% YoY from Rs 172 crore in Q4 FY25. Results declared May 18, 2026. Full details from NSE/BSE regulatory filings. Verify all data before investing.

What is the company’s revenue?

Ans. The firm’s revenue from operations was Rs 1,485 crore for the quarter ended March 31, 2026. Track live on the Univest Screener.

When were Zydus results announced?

Ans. The company results were announced on May 18, 2026, at the board meeting approving audited Q4 and FY26 financial statements for the year ended March 31, 2026.

Is Zydus Wellness a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, sector dynamics, and personal risk tolerance. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.